...
首页> 外文期刊>Dose-response >Combination of β Adrenergic Receptor Block and Renin–Angiotensin System Inhibition Diminished the Angiotensin II-Induced Vasoconstriction and Increased Bradykinin-Induced Vasodilation in Hypertension
【24h】

Combination of β Adrenergic Receptor Block and Renin–Angiotensin System Inhibition Diminished the Angiotensin II-Induced Vasoconstriction and Increased Bradykinin-Induced Vasodilation in Hypertension

机译:β肾上腺素受体阻滞剂和肾素-血管紧张素系统抑制的组合减少高血压中血管紧张素II诱导的血管收缩和缓激肽诱导的血管舒张增加

获取原文
   

获取外文期刊封面封底 >>

       

摘要

In hypertension, the combination therapy is frequently used to obtain a better therapeutic effect and reduce adverse effects. One effective combination is with inhibitors and β-blockers of renin–angiotensin system. Although the mechanisms of action of each drug are already known, the antihypertensive mechanism is more complex and therefore the combined treatment mechanism is unclear. Specifically, the effect of the treatments of angiotensin-converting enzyme inhibitor or AT1 receptor antagonist with β-blocker on the angiotensin II and bradykinin reactivity has not been studied. For this reason, we evaluated the interaction between propranolol and captopril or losartan on vascular reactivity to bradykinin and angiotensin II in spontaneously hypertensive rat. We constructed concentration–response curves to angiotensin II and bradykinin after treatment of SHR with propranolol–captopril or propranolol–losartan by using rat aortic rings. While losartan or captopril with propranolol potentiated bradykinin-induced vasodilation effect, the propranolol–losartan interaction decreased the angiotensin II-induced vasoconstriction. In addition, the combinations did not reduce the heart rate significantly. These results suggest that the combined therapy decreased blood pressure to normotensive values and showed less effect for angiotensin II and greater effect for bradykinin than monotherapy which could contribute in the antihypertensive effect.
机译:在高血压中,联合疗法经常用于获得更好的治疗效果并减少不良反应。一种有效的组合是与肾素-血管紧张素系统的抑制剂和β-受体阻滞剂结合。尽管每种药物的作用机制是已知的,但降压机制更为复杂,因此尚不清楚联合治疗机制。具体而言,尚未研究用β受体阻滞剂治疗血管紧张素转化酶抑制剂或AT 1 受体拮抗剂对血管紧张素II和缓激肽反应性的影响。因此,我们评估了自发性高血压大鼠中心得安与卡托普利或氯沙坦之间对缓激肽和血管紧张素II血管反应性的相互作用。我们通过使用大鼠主动脉环,用普萘洛尔-卡托普利或普萘洛尔-氯沙坦治疗SHR后,构建了对血管紧张素II和缓激肽的浓度-反应曲线。当氯沙坦或卡托普利与普萘洛尔一起增强缓激肽诱导的血管舒张作用时,普萘洛尔与氯沙坦的相互作用降低了血管紧张素Ⅱ诱导的血管收缩。此外,这些组合并未显着降低心率。这些结果表明,与单一疗法相比,联合疗法可将血压降低至血压正常值,对血管紧张素II的作用较小,对缓激肽的作用更大,这可能有助于降压作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号